Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 1164 results for criteria

  1. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA763

  2. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

    Technology appraisal guidance
    Published
    21 February 2024
    View recommendations

    Sections for TA952

  3. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.

    Technology appraisal guidance
    Published
    4 October 2017
    View recommendations

    Sections for TA478

  4. NaviCam for diagnosing gastrointestinal tract conditions (MIB104)

    NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .

    Medtech innovation briefing
    Published
    11 May 2017

  5. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  6. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  7. Risk assessment for black, Asian and minority ethnic groups: What is the accuracy of the 4-variable Kidney Failure Risk Equation in adults, children and young people with CKD from black, Asian and minority ethnic groups living in the UK?

    recommendation for research, see the rationale on risk assessment, referral criteria and shared care. Full details of the evidence and...

    Research recommendation
    Published
    30 September 2021

  8. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA181

  9. Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

    Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    11 January 2023
    View recommendations

    Sections for TA858

  10. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)

    Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.

    Technology appraisal guidance
    Published
    19 February 2025
    View recommendations

    Sections for TA1042

  11. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  12. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    9 August 2017
    View recommendations

    Sections for TA463

  13. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

    Technology appraisal guidance
    Published
    3 September 2025
    View recommendations

    Sections for TA1096

  14. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

    NICE guideline
    Last updated
    30 January 2025

    Sections for NG217

  15. Embryo selection for single embryo transfer:- Further research is needed to improve embryo selection to facilitate single embryo transfers.

    based on the assessment of developmental stage and morphological grading criteria in the laboratory. These features are indicative of...

    Research recommendation
    Published
    9 June 2015